Hoth Therapeutics Unveils Promising HT-001 Data for Cancer Patients with Skin Toxicities#United_States#New_York#Hoth_Therapeutics#HT-001#EGFR_Therapy
Hoth Therapeutics Unveils Promising HT-001 Data for Cancer Patients with Skin Toxicities
Hoth Therapeutics has announced remarkable results from the HT-001 study, showcasing improved drug exposure and safety for cancer patients suffering skin toxicities.
third-news.com
March 24, 2026 at 1:02 PM
Hoth Therapeutics Unveils Promising HT-001 Data for Cancer Patients with Skin Toxicities#United_States#New_York#Hoth_Therapeutics#HT-001#EGFR_Therapy
Kowa's Innovative Antibody-Drug Conjugate Offers New Hope Against EGFR-Expressing Solid Tumors#Japan#Nagoya#K-679#Kowa_Company#EGFR_Therapy
Kowa's Innovative Antibody-Drug Conjugate Offers New Hope Against EGFR-Expressing Solid Tumors
Kowa Company, Ltd. announced significant findings for K-679, a novel antibody-drug conjugate demonstrating superior efficacy in treating solid tumors that express EGFR. The breakthrough highlights advances in cancer therapy.
third-news.com
April 21, 2025 at 8:13 AM
Kowa's Innovative Antibody-Drug Conjugate Offers New Hope Against EGFR-Expressing Solid Tumors#Japan#Nagoya#K-679#Kowa_Company#EGFR_Therapy